News
BAYZF
38.70
-3.30%
-1.32
Goldman Sachs Group Increases Total Voting Rights in Bayer AG to 5.41%
Reuters · 1d ago
Santen and Bayer Secure NHI Listing for Aflibercept Injection Kit in Japan
Reuters · 1d ago
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
Seeking Alpha · 2d ago
Goldman Sachs Group Increases Total Voting Rights in Bayer AG to 3.17%
Reuters · 2d ago
Bayer initiates clinical trial with BAY 3401016
TipRanks · 2d ago
Evotec SE and Bayer Launch Phase 2 Trial of SEMA3A Antibody for Alport Syndrome
Reuters · 2d ago
Bayer Launches Phase IIa Trial of BAY 3401016 for Alport Syndrome
Reuters · 2d ago
Kepler Capital Sticks to Their Buy Rating for Bayer (0P6S)
TipRanks · 2d ago
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
Barchart · 2d ago
Bayer says Gadoquatrane met primary, secondary endpoints in trial
TipRanks · 3d ago
Bayer releases data for contrast agent gadoquatrane in children
Seeking Alpha · 3d ago
Reuters Sustainable Finance Newsletter - Trump-Hamas negotiator says businesses can lean on Israel
Reuters · 3d ago
Bayer Unveils Positive Pediatric Study Results for Low-Dose MRI Contrast Agent Gadoquatrane
Reuters · 3d ago
Bayer (0P6S) Receives a Buy from DZ BANK AG
TipRanks · 3d ago
LIVE MARKETS-When crypto prices tumbled, what of the corporate hoarders?
Reuters · 4d ago
Barclays Reaffirms Their Hold Rating on Bayer (0P6S)
TipRanks · 4d ago
LIVE MARKETS-Benchmark Treasury yield still a coiled spring  
Reuters · 4d ago
Bayer welcomes Solicitor General support for U.S. Supreme Court review
TipRanks · 4d ago
Bayer starts SUNFLOWER study
TipRanks · 4d ago
BAYER AG - STARTS NEW PHASE III STUDY WITH MIRENA® FOR TREATMENT OF NONATYPICAL ENDOMETRIAL HYPERPLASIA
Reuters · 4d ago
More
Webull provides a variety of real-time BAYZF stock news. You can receive the latest news about Bayer A G through multiple platforms. This information may help you make smarter investment decisions.
About BAYZF
Bayer AG is a German-based life science company. The Company's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.